A Look At Zoetis (ZTS) Valuation After Librela Setbacks And Guidance Cut

Conference spotlight and recent sentiment shift

Zoetis (ZTS) is back in focus as Senior VP of Global Biologics R&D, Mahesh Kumar, presents at the World Vaccine Congress Washington 2026. The event is drawing attention to the company after a stretch of weaker investor sentiment.

Recent setbacks around its osteoarthritis drug Librela, increased competition, negative social media coverage, and lowered annual guidance have weighed on the stock. This comes despite Zoetis previously exceeding consensus earnings per share expectations.

See our latest analysis for Zoetis.

At a share price of US$118.21, Zoetis is up over the past week but shows a 1 month share price return of 9.8% decline and a 1 year total shareholder return of 25.9% loss. This suggests momentum has faded as Librela setbacks and guidance cuts reset expectations.

If this has you reassessing your watchlist, it may be a good moment to broaden your search with a curated list of 34 healthcare AI stocks.

With Zoetis trading at US$118.21 after a 9.8% 1 month decline and a 25.9% 1 year total shareholder loss, you now need to ask: is this weakness an opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 22% Undervalued

Zoetis closed at US$118.21 against a widely followed fair value estimate of US$151.00, which frames the current pullback as a discount in that narrative.

Unmet demand in both companion animal and livestock markets continues to provide significant room for revenue expansion, as millions of pets (especially those with dermatological and chronic pain conditions) remain untreated or under-treated, and growing global protein consumption fuels the need for animal health solutions, driving both top-line and recurring revenue growth.

Read the complete narrative.

Curious what sits behind that fair value gap? The narrative leans on steady earnings growth, firm margins, and a future profit multiple that assumes resilient demand and ongoing product traction.

Result: Fair Value of US$151 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that fair value gap can close quickly if competition bites into key franchises or if the osteoarthritis portfolio, including Librela, fails to meet expectations.

Find out about the key risks to this Zoetis narrative.

Next Steps

With sentiment clearly mixed, this is the moment to look through the numbers yourself, weigh the challenges against the upside, and review the full balance of 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Zoetis is already on your radar, do not stop there. Use the screener to uncover fresh ideas that match your goals before the market moves first.

• Target resilient cash generators by scanning for companies in the solid balance sheet and fundamentals stocks screener (39 results) that can help anchor your portfolio.
• Hunt for potential bargains by reviewing the 58 high quality undervalued stocks that combine quality with pricing that may appeal to value focused investors.
• Build a watchlist of future front runners by searching the screener containing 25 high quality undiscovered gems before other investors start paying closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com